Ypsomed Holding AG (SWX:YPSN)
412.50
+2.50 (0.61%)
Jun 5, 2025, 5:31 PM CET
Ypsomed Holding AG Revenue
In the fiscal year ending March 31, 2025, Ypsomed Holding AG had annual revenue of 748.87M CHF with 36.54% growth. Ypsomed Holding AG had revenue of 424.86M in the half year ending March 31, 2025, with 67.79% growth.
Revenue
748.87M
Revenue Growth
+36.54%
P/S Ratio
7.52
Revenue / Employee
283.23K
Employees
2,644
Market Cap
5.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 748.87M | 200.41M | 36.54% |
Mar 31, 2024 | 548.46M | 51.00M | 10.25% |
Mar 31, 2023 | 497.46M | 32.62M | 7.02% |
Mar 31, 2022 | 464.84M | 61.19M | 15.16% |
Mar 31, 2021 | 403.66M | 9.39M | 2.38% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 62.40B |
Novartis AG | 47.05B |
Lonza Group AG | 6.57B |
Alcon | 8.77B |
Galderma Group AG | 4.02B |
Sandoz Group AG | 9.41B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG News
- 6 months ago - Novo Nordisk (NVO) Partners with Ypsomed for Next-Gen Obesity Drug Delivery - GuruFocus
- 6 months ago - Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens - Seeking Alpha